Zoledronic Acid May Reduce Intraoperative Bleeding in Spinal Tumors: A Prospective Cohort Study

<div class="floats-full-page floats-full-page-other"><h2>Table 2</h2><div class="floats-full-page-caption">Baseline characteristics in 19 patients with multiple myeloma<sup>a</sup>.</div><div class="floats-full-page-content"><table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="4"><hr /></td></tr><tr class="thead"><td align="left">Characteristic</td><td align="center">Preoperative zoledronic acid group (group C; <svg height="8.91176pt" id="M29" style="vertical-align:-0.2130003pt" version="1.1" viewbox="-0.0498162 -8.69876 35.534 8.91176" width="35.534pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.0135,0,0,-0.0135,0,0)"><path d="M495 86L479 114C446 82 419 66 409 66C401 66 401 72 406 97C420 166 436 231 453 297C489 435 454 448 428 448C406 448 384 439 354 422C305 394 222 327 161 247H159L183 345C200 415 194 448 173 448C143 448 82 410 23 351L38 325C64 349 95 371 105 371C111 371 116 365 109 336L25 -4L31 -12C50 -4 77 3 107 9C119 69 132 122 145 168C197 254 321 381 370 381C387 381 393 374 378 305L329 95C309 17 320 -12 345 -12C372 -12 430 19 495 86Z" id="g113-111"></path><glyph.data ascent="3473" descent="-2876" horiz-adv-x="502" vert-adv-y="502"></glyph.data></g><g transform="matrix(.0135,0,0,-0.0135,10.586,0)"><path d="M535 323V373H52V323H535ZM535 138V188H52V138H535Z" id="g117-34"></path><glyph.data ascent="3473" descent="-2876" horiz-adv-x="587" vert-adv-y="587"></glyph.data></g><g transform="matrix(.0135,0,0,-0.0135,22.324,0)"><path d="M384 0V27C293 34 287 42 287 114V635C232 613 172 594 109 583V559L157 557C201 555 205 550 205 499V114C205 42 199 34 109 27V0H384Z" id="g113-50"></path><glyph.data ascent="3473" descent="-2876" horiz-adv-x="480" vert-adv-y="480"></glyph.data></g><g transform="matrix(.0135,0,0,-0.0135,28.827,0)"><path d="M241 635C89 635 35 457 35 312C35 153 89 -12 240 -12C390 -12 443 166 443 312C443 466 390 635 241 635ZM238 602C329 602 354 454 354 312C354 172 330 22 240 22C152 22 124 173 124 313S148 602 238 602Z" id="g113-49"></path><glyph.data ascent="3473" descent="-2876" horiz-adv-x="480" vert-adv-y="480"></glyph.data></g></svg>)</td><td align="center">Control group (group D; <svg height="8.91176pt" id="M30" style="vertical-align:-0.2130003pt" version="1.1" viewbox="-0.0498162 -8.69876 29.0064 8.91176" width="29.0064pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.0135,0,0,-0.0135,0,0)"><path d="M495 86L479 114C446 82 419 66 409 66C401 66 401 72 406 97C420 166 436 231 453 297C489 435 454 448 428 448C406 448 384 439 354 422C305 394 222 327 161 247H159L183 345C200 415 194 448 173 448C143 448 82 410 23 351L38 325C64 349 95 371 105 371C111 371 116 365 109 336L25 -4L31 -12C50 -4 77 3 107 9C119 69 132 122 145 168C197 254 321 381 370 381C387 381 393 374 378 305L329 95C309 17 320 -12 345 -12C372 -12 430 19 495 86Z" id="g113-111"></path><glyph.data ascent="3473" descent="-2876" horiz-adv-x="502" vert-adv-y="502"></glyph.data></g><g transform="matrix(.0135,0,0,-0.0135,10.586,0)"><path d="M535 323V373H52V323H535ZM535 138V188H52V138H535Z" id="g117-34"></path><glyph.data ascent="3473" descent="-2876" horiz-adv-x="587" vert-adv-y="587"></glyph.data></g><g transform="matrix(.0135,0,0,-0.0135,22.324,0)"><path d="M244 635C114 635 38 519 38 422C38 317 111 240 217 240C236 240 255 244 277 256L345 292C311 140 203 39 59 15L64 -15C89 -15 150 -5 204 17C339 72 440 202 440 386C440 521 368 635 244 635ZM228 602C326 602 352 479 352 390C352 370 351 347 348 324C327 308 293 296 258 296C174 296 124 369 124 458C124 517 152 602 228 602Z" id="g113-58"></path><glyph.data ascent="3473" descent="-2876" horiz-adv-x="480" vert-adv-y="480"></glyph.data></g></svg>)</td><td align="center"><span style="width: 8.4902ptpx;"><svg height="9.04777pt" id="M31" style="vertical-align:-0.04981995pt" version="1.1" viewbox="-0.0498162 -8.99795 8.4902 9.04777" width="8.4902pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.0135,0,0,-0.0135,0,0)"><path d="M600 480C600 590 528 650 384 650H143L137 622C222 614 225 607 210 531L130 127C113 41 106 36 23 28L17 0H294L300 28C204 36 195 42 212 127L243 284L314 263C327 263 339 263 352 264C465 271 600 337 600 480ZM508 481C508 351 402 304 329 304C289 304 265 311 250 317L295 559C302 594 310 606 323 611C335 616 350 619 367 619C455 619 508 573 508 481Z" id="g113-81"></path><glyph.data ascent="3473" descent="-2876" horiz-adv-x="617" vert-adv-y="617"></glyph.data></g></svg></span></td></tr><tr><td class="thead-hr" colspan="4"><hr /></td></tr><tr><td align="left">Sex</td><td align="center"> </td><td align="center"> </td><td align="center">0.876</td></tr><tr><td align="left"> Men</td><td align="center">7</td><td align="center">6</td><td align="center"> </td></tr><tr><td align="left"> Women</td><td align="center">3</td><td align="center">3</td><td align="center"> </td></tr><tr><td align="left">Age (y)</td><td align="center"> </td><td align="center"> </td><td align="center">0.283</td></tr><tr><td align="left"> Mean ± SD</td><td align="center">63.8 ± 4.5</td><td align="center">61.7 ± 3.7</td><td align="center"> </td></tr><tr><td align="left"> Range</td><td align="center">55–70</td><td align="center">57–67</td><td align="center"> </td></tr><tr><td align="left">Preoperative Frankel score</td><td align="center"> </td><td align="center"> </td><td align="center">0.322</td></tr><tr><td align="left"> A</td><td align="center">0</td><td align="center">0</td><td align="center"> </td></tr><tr><td align="left"> B</td><td align="center">2</td><td align="center">0</td><td align="center"> </td></tr><tr><td align="left"> C</td><td align="center">2</td><td align="center">4</td><td align="center"> </td></tr><tr><td align="left"> D</td><td align="center">4</td><td align="center">2</td><td align="center"> </td></tr><tr><td align="left"> E</td><td align="center">2</td><td align="center">3</td><td align="center"> </td></tr><tr><td align="left">Number of spinal metastases</td><td align="center"> </td><td align="center"> </td><td align="center">0.498</td></tr><tr><td align="left"> Single</td><td align="center">4</td><td align="center">5</td><td align="center"> </td></tr><tr><td align="left"> Multiple</td><td align="center">6</td><td align="center">4</td><td align="center"> </td></tr><tr><td align="left">Tumor location</td><td align="center"> </td><td align="center"> </td><td align="center">0.795</td></tr><tr><td align="left"> Cervical</td><td align="center">2</td><td align="center">3</td><td align="center"> </td></tr><tr><td align="left"> Thoracic</td><td align="center">5</td><td align="center">4</td><td align="center"> </td></tr><tr><td align="left"> Lumbar</td><td align="center">3</td><td align="center">2</td><td align="center"> </td></tr><tr class="table-tr"><td colspan="4"><hr class="tbody-hr" /></td></tr></table></td></tr><tr class="table-fn"><td>SD: standard deviation.<br /><sup>&#13;
                  a</sup>The Student’s <svg height="8.35422pt" id="M32" style="vertical-align:-0.2130003pt" version="1.1" viewbox="-0.0498162 -8.14122 4.73688 8.35422" width="4.73688pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.0135,0,0,-0.0135,0,0)"><path d="M324 430H196L233 583L223 592L145 529L120 430H54L29 396L31 388H111L56 126C33 15 54 -12 77 -12C137 -12 214 57 250 95L233 119C208 92 155 59 138 59C126 59 120 70 131 125L186 390L298 394L324 430Z" id="g113-117"></path><glyph.data ascent="3473" descent="-2876" horiz-adv-x="341" vert-adv-y="341"></glyph.data></g></svg>-test was used for continuous variables, and chi-square analysis was used for categorical variables.<br /></td></tr></table></div></div>

Table 2 | Zoledronic Acid May Reduce Intraoperative Bleeding in Spinal Tumors: A Prospective Cohort Study

title

Table 2: Zoledronic Acid May Reduce Intraoperative Bleeding in Spinal Tumors: A Prospective Cohort Study

description

Table 2

About this journal

<p><em>BioMed Research International</em> publishes original research articles, review articles, and clinical studies covering a wide range of subjects within the biomedical sciences. The journal will accept both basic and translational research.</p>


Journal profile

Meet the editorial board

<p><em>BioMed Research International</em> maintains an Editorial Board of practicing researchers from around the world, to ensure manuscripts are handled by editors who are experts in the field of study.</p>


Editor spotlight

Submit to Special Issue

We currently have a number of Special Issues open for submission. Special Issues highlight emerging areas of research within a field, or provide a venue for a deeper investigation into an existing research area.